Costs Still on the Rise for Drugs for Neurological Diseases

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer’s, and Parkinson’s disease continues to rise, especially for MS drugs, according to a study published in the October 30, 2024, online issue of Neurology(r), the medical journal of the American Academy of Neurology. 

Read More